Latest News

STAT Plus: More larger-cap biopharma companies faced securities fraud lawsuits than ever





The number of class-action lawsuits claiming securities fraud committed by life sciences companies leveled off last year, but a new trend emerged — unlike in the past, when most suits targeted small-cap companies, more cases involved drug or device makers with market caps of $500 million or more.

A total of 86 class action securities lawsuits were filed against life sciences companies in 2018, a drop from 88 lawsuits filed the year before. Even so, this still represented a 352 percent rise from 19 such lawsuits that were filed in 2013, according to the Dechert law firm, which conducted the latest analysis.

Continue to STAT Plus to read the full story…

Source link







WordPress database error: [Error writing file '/tmp/MYhM01un' (Errcode: 28 - No space left on device)]
SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) WHERE 1=1 AND wp_posts.ID NOT IN (151257) AND ( wp_term_relationships.term_taxonomy_id IN (2) ) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish') GROUP BY wp_posts.ID ORDER BY RAND() LIMIT 0, 3

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy